Navigation Links
Anti-Retroviral Therapies Associated with Reduced Infections in HIV-Infected Children

Since the introduction of highly active antiretroviral therapies, there has been a substantial reduction of opportunistic infections and other infections in HIV-infected children,// such as pneumonia and tuberculosis, according to a study.

The human immunodeficiency virus (HIV) epidemic has spurred the development of new antiretroviral, immune, and vaccine-based therapies geared to block transmission, prevent disease progression, and prolong the survival of individuals who are HIV positive, according to background information in the article. Highly active antiretroviral therapy (HAART) has dramatically decreased rates of AIDS-related opportunistic infections (infections caused by an organism capable of causing disease in a host whose resistance is lowered, e.g., by other diseases or by drugs) and deaths in adults. Although HAART has dramatically decreased illness and death in HIV-infected infants, children, and adolescents in the United States, no studies comparing the incidence of opportunistic and other related infections before and during the HAART era have been conducted.

Philimon Gona, Ph.D., of the Harvard School of Public Health and Boston University, Boston, and colleagues estimated the rates for the first occurrence of 29 targeted opportunistic and other related infections between Jan. 1, 2001, and Dec. 31, 2004, in HIV-infected infants, children, and adolescents to compare the rates in the HAART era to those of the pre-HAART era. The study included 2,767 children enrolled between Sept. 15, 2000, and Dec. 31, 2004, with information entered in the database up to August 1, 2005, when data analysis was conducted. The pre-HAART era comparison population included 3,331 children enrolled in 13 Pediatric AIDS Clinical Trials Group (PACTG) protocols from October 1988 to August 1998.

Seventy-five percent of the children were enrolled in 2000 and 2001. Overall, 553 first episodes of a specific infection occurred among 395 (14 percen t) of the study participants. The incidence rates (IRs) per 100 person-years for the 4 most common first-time infections were bacterial pneumonia (IR, 2.15), herpes zoster (IR, 1.11), dermatophyte infections (IR, 0.88), and oral candidiasis (IR, 0.93). Infection rates were significantly lower than those reported in the PACTG in the pre-HAART era: bacterial pneumonia (IR, 11.1), bacteremia (IR, 3.3), herpes zoster (IR, 2.9), oral candidiasis (IR, 1.2) and tuberculosis (IR, 0.2).

“Despite these current advances due to HAART, some HIV-infected children continue to develop opportunistic infections. Some children fail to respond to antiretroviral therapy as a result of viral resistance, poor adherence, or inability to tolerate complex treatment regimens. Furthermore, prophylactic [preventive] therapies are not fully effective and poor adherence can further reduce their efficacy. Drug interactions, complex dosing schedules, adverse effects, and high costs can further limit the efficacy of these therapies. Although these issues do present challenges, our findings demonstrate a substantial reduction in the incidence of several opportunistic infections in HIV-infected children since the introduction of HAART therapy,” the authors write.

(Source: Newswise)
'"/>




Related medicine news :

1. Anti-Retrovirals in Africa, not a distant dream
2. Anti-Retrovirals Capable of Halting Mental Illness in HIV Patients
3. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
4. Preventive Therapies Found to be More Effective in Managing Migraines
5. Ayurvedic Therapies Cashing In On Medical Tourism
6. Immune-Boosting Therapies Of No Use In Preventing Miscarriage
7. Non Hormonal Therapies for Menopause Not Proved to be Effective
8. Need for More Talking Therapies for Treating Depression
9. Are Alternative Therapies A Reliable Alternative?
10. Special Behavioral Therapies made Women more likely to Attempt Suicide
11. Alternative Therapies May Not Ease Menopause Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... ... February 22, 2017 , ... ... of African American/Black students who want to become physicians. PMF also provides a ... as physicians in the Oakland/San Francisco Northern California, Bay Area. PMF’s mission is ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... Marc Philpart, senior director at PolicyLink, will be the keynote speaker at its ... Boys and Men of Color Framework, which develops comprehensive strategies to create and ...
(Date:2/21/2017)... ... ... Ray Insurance Agencies, a Dallas area firm providing asset protection services and ... six month charity event aimed at raising local support and donations that will be ... deadliest diseases in America; more than 7.5 million people die from cancer related disorders ...
(Date:2/21/2017)... ... February 21, 2017 , ... Each February ... History Month (officially African American History Month ). This month-long ... of a diverse race of people, but also the opportunity to examine the ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... , Feb. 21, 2017 Medical Oxygen ... report: http://www.reportlinker.com/p04711311-summary/view-report.html Medical oxygen concentrators ... other respiratory diseases. Patients having low level of ... oxygen concentrators. Oxygen concentrators are to be used ... the counter. Medical oxygen concentrators work either on ...
(Date:2/21/2017)... , Feb. 21, 2017   BeyondSpring Pharmaceuticals ... the development of innovative immuno-oncology cancer therapies, today ... data from its Phase 2 trial of BeyondSpring,s ... treatment of non-small cell lung cancer (NSCLC) with ... this year,s ASCO-SITC Clinical Immuno-Oncology Symposium in ...
Breaking Medicine Technology: